JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
复制标题
JAK1作为乳腺癌的预后标志物及其与免疫浸润的相关性
DOI：
10.18632/aging.102514
复制
发表时间：
2019-12-15
期刊：
影响因子：
5.2
通讯作者：
Liao, Ning
中科院分区：
文献类型：
--
作者：
Chen, Bo;Lai, Jianguo;Liao, Ning
在癌症中测试Janus激酶-1（JAK 1）抑制剂的临床试验正在进行中。乳腺肿瘤中JAK 1 mRNA水平是否与结果相关尚未评估。JAK 1表达通过Oncomine数据库和Tumor IMmune Estimation Resource网站进行分析。来自57名乳腺癌患者的肿瘤组织用于qRT-PCR和免疫浸润评估。JAK 1在乳腺浸润癌中的表达明显低于癌旁正常组织。公共数据库（Kaplan-Meier Kaplan-Meier和PrognoScan）显示，JAK 1低表达与较差的生存率相关。来自癌症基因组图谱（TCGA）的数据显示，JAK 1高表达与TNM I-II和TNM III-IV患者的生存率增加相关。JAK 1与乳腺癌患者的肿瘤大小状态、淋巴结状态和TNM呈负相关。JAK 1水平与T细胞转录物富集的LYM多基因特征相关，并且在低肿瘤浸润淋巴细胞（TIL）组中显著较低。JAK 1表达水平与乳腺癌中CD 8 + T细胞、CD 4 + T细胞、巨噬细胞、中性粒细胞和树突状细胞的浸润水平显著正相关，而与其他B细胞无关。JAK 1 mRNA表达水平与乳腺癌的预后和免疫浸润水平相关。
Clinical trials testing Janus kinase-1 (JAK1) inhibitors in cancers are under way. Whether the JAK1 mRNA levels in breast tumors correlates with outcome has not been evaluated. JAK1 expression was analyzed via the Oncomine database and Tumor IMmune Estimation Resource site. Tumor tissues from 57 breast cancer patients were used for qRT-PCR and immune infiltration assessment. JAK1 expression was significantly lower in breast invasive carcinoma compared with adjacent normal tissues. Public databases (Kaplan-Meier plotter and PrognoScan) showed that low JAK1 expression was associated with poorer survival. Data from The Cancer Genome Atlas (TCGA) showed that high JAK1 expression was associated with increased survival in both TNM I-II and TNM III-IV patients. JAK1 was inversely correlated with tumor size status, lymph node status, and TNM of breast cancer patients. JAK1 levels were correlated with the T cell transcript-enriched LYM metagene signature and was significantly lower in the low tumor infiltrating lymphocytes (TILs) group. JAK1 expression levels had significant positive correlations with infiltrating levels of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in breast cancer and not with other B cells. In conclusion, JAK1 mRNA levels were correlated with prognosis and immune infiltrating levels in breast cancer.